- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.12.2025 | 467 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 18.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.12.2025ISIN NameAU000000WLD8 WELLARD... ► Artikel lesen | |
| 16.12.25 | XFRA 99B0: AUSSETZUNG/SUSPENSION | 160 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILQUIA PHARMA AB O.N.... ► Artikel lesen | |
| 17.11.25 | The observation status for QUIA PHARMA AB (publ) is updated | 158 | GlobeNewswire | On June 12, 2025, the shares in QUIA PHARMA AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
The... ► Artikel lesen | |
| 17.11.25 | Delisting of QUIA PHARMA AB (publ) from Nasdaq First North Growth Market | 206 | GlobeNewswire | According to item 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to item 1.4.2 of the Nasdaq First North... ► Artikel lesen | |
| 12.06.25 | QUIA PHARMA AB (publ) receives observation status | 314 | GlobeNewswire | On June 5, 2025, QUIA PHARMA AB (publ) (the "Company") disclosed its annual financial report for 2024 with information on the Company's financial situation.
The rules of Nasdaq First North... ► Artikel lesen | |
| 04.04.25 | Decision by the Disciplinary Committee regarding QUIA PHARMA AB (publ) | 483 | GlobeNewswire | Stockholm, April 4, 2025- The Disciplinary Committee of Nasdaq Stockholm (the "Exchange") has found that QUIA PHARMA AB (publ) (the "Company") has breached the rules of Nasdaq First North Growth... ► Artikel lesen | |
| QUIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 17.02.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.02.2025 | 1.452 | Xetra Newsboard | Das Instrument 99B0 SE0020678159 QUIA PHARMA AB O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 17.02.2025 und ex Kapitalmassnahme am 18.02.2025 The instrument 99B0 SE0020678159 QUIA PHARMA AB O.N.... ► Artikel lesen | |
| 23.01.25 | Nasdaq Stockholm AB: QUIA PHARMA AB (publ) receives observation status | 395 | GlobeNewswire | On November 25, 2024, QUIA PHARMA AB (publ) (the "Company") disclosed a press release with information that the Company had received a Statement of Reprimand from Nasdaq Stockholm AB expressing the... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 294,38 | +0,63 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,880 | +1,01 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,690 | -2,03 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,310 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,570 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,000 | 0,00 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| ALUMIS | 18,170 | 0,00 % | What's Going On With Alumis Stock Thursday? | ||
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 66,98 | +1,15 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| ERASCA | 5,840 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| RECURSION PHARMACEUTICALS | 4,700 | -3,29 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates |
QUIA PHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QUIA PHARMA AB finden Sie auf Wallstreet Online.